Toripalimab and Penpulimab: Targeting PD-1 in Recurrent or Metastatic Nasopharyngeal Carcinoma

Toripalimab and penpulimab significantly improve outcomes in RM-NPC. Their use is anticipated to expand into additional settings and malignancies as research matures.

Authors

Institutions

Publication Details

Journal
Annals of Pharmacotherapy
Published
2025-12-01
DOI
https://doi.org/10.1177/10600280251391430
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Toripalimab and Penpulimab: Targeting PD-1 in Recurrent or Metastatic Nasopharyngeal Carcinoma

Michael D. Keller, David J. Reeves, Josie J. Hockett
Annals of Pharmacotherapy
Head and Neck Cancer Studies
article

Toripalimab and Penpulimab: Targeting PD-1 in Recurrent or Metastatic Nasopharyngeal Carcinoma

Michael D. Keller, David J. Reeves, Josie J. Hockett
article en

Abstract

Toripalimab and penpulimab significantly improve outcomes in RM-NPC. Their use is anticipated to expand into additional settings and malignancies as research matures.

Annals of Pharmacotherapy
Butler University (US), Franciscan Health Indianapolis (US)
Openalex Percentile: Top 48%
Head and Neck Cancer Studies
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Toripalimab and Penpulimab: Targeting PD-1 in Recurrent or Metastatic Nasopharyngeal Carcinoma — Michael D. Keller, David J. Reeves, et al. · Annals of Pharmacotherapy (2025) | TGRS Research Map | TGRS